Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection
- 19 August 2014
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (12), 3282-3293
- https://doi.org/10.1093/jac/dku318
Abstract
Over-the-counter access to an inexpensive, effective topical microbicide could reduce the transmission of HIV and would increase women's control over their health and eliminate the need to obtain their partners' consent for prophylaxis. Chronic infection with herpes simplex virus 2 (HSV-2), also known as human herpes virus 2, has been shown to facilitate HIV infection and speed the progression to immunodeficiency disease. Our objective is to develop a drug formulation that protects against both HSV-2 and HIV infection and adheres to the vaginal surface with extended residence time. We developed a formulation using two approved antiviral active pharmaceutical ingredients, aciclovir and tenofovir, in a novel bioadhesive vaginal delivery platform (designated SR-2P) composed of two polymers, poloxamer 407 NF (Pluronic® F-127) and polycarbophil USP (Noveon® AA-1). The efficacy of the formulation to protect from HSV-2 infection was tested in vitro and in vivo. In addition to its efficacy, it is essential for a successful microbicide to be non-irritating to the vaginal mucosa. We therefore tested our SR-2P platform gel in the FDA gold-standard microbicide safety model in rabbits and also in a rat vaginal irritation model. Our studies indicated that SR-2P containing 1% aciclovir and 5% tenofovir protects (i) Vero cells from HSV-2 infection in vitro and (ii) mice from HSV-2 infection in vivo. Our results further demonstrated that SR-2P was not irritating in either vaginal irritation model. We conclude that SR-2P containing aciclovir and tenofovir may be a suitable candidate microbicide to protect humans from vaginal HSV-2 infection.Keywords
This publication has 48 references indexed in Scilit:
- Simultaneous Delivery of Tenofovir and Acyclovir via an Intravaginal RingAntimicrobial Agents and Chemotherapy, 2012
- Tenofovir-based pre-exposure prophylaxis for HIV preventionCurrent Opinion in Infectious Diseases, 2012
- Zinc Acetate/Carrageenan Gels Exhibit Potent Activity In Vivo against High-Dose Herpes Simplex Virus 2 Vaginal and Rectal ChallengeAntimicrobial Agents and Chemotherapy, 2012
- Pharmacokinetics of Tenofovir following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus MacaquesAntimicrobial Agents and Chemotherapy, 2012
- Topical microbicides to prevent the transmission of HIV: formulation gaps and challengesDrug Delivery and Translational Research, 2011
- Impact of Valency of a Glycoprotein B-Specific Monoclonal Antibody on Neutralization of Herpes Simplex VirusJournal of Virology, 2011
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- Contribution of sexually transmitted infections to the sexual transmission of HIVCurrent Opinion in HIV and AIDS, 2010
- Development of a Comprehensive Human Immunodeficiency Virus Type 1 Screening Algorithm for Discovery and Preclinical Testing of Topical MicrobicidesAntimicrobial Agents and Chemotherapy, 2008
- Final Amended Report on the Safety Assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in Cosmetic ProductsInternational Journal of Toxicology, 2008